Press 2021-04-19T06:44:29+00:00

July 21, 2020– Innate Repair Activator Cibinetide Shows Potential for Efficacy in Diabetic Macular Edema
November 21, 2019– Araim Pharmaceuticals Selects Ferry Breedveld as Acting CEO
April 1, 2019– Araim’s Cibinetide Enhances Endothelial Stem Cell Mediated Vascular Regeneration for Treatment of Retinal Ischemia
May 16, 2018– Araim’s Cibinetide in Inflammatory and Autoimmune Diseases:Increasing Evidence for Immune Modulation and Pleiotropic Benefit
May 2, 2018– New Research Shows Promising Signs in Anti-Aging for Araim Pharmaceuticals
April 2, 2018– Prestigious Paul Ehrlich Award Bestowed Upon Araim Pharmaceuticals Founder, Anthony Cerami
December 19, 2017– Araim Pharmaceuticals’ Innate Repair Receptor Activating Compound Accelerates Healing of Diabetic Wounds
December 19, 2017– OPIOID EPIDEMIC Impacts Patients Suffering from Orphan Disease of Sarcoidosis
May 9, 2017- Araim Pharmaceuticals’ Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis
November 28, 2016 – ARA 290 Obtains European Union Orphan Drug Designation for Prevention of Graft Loss in Pancreatic Islet Transplantation
August 08, 2016Araim Pharmaceuticals Announces Appointment of Ferdinand C. Breedveld, M.D. as Chairman of the Board
July 25, 2016Araim Pharmaceuticals Obtains Fourth Orphan Designation: ARA 290 Obtains US Orphan Drug Designation for Treatment to Increase Survival and Improve Functioning of Pancreatic Islets Following Transplantation
July 5, 2016 Araim Pharmaceuticals Receives Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosis
May 10, 2016Queen’s University Belfast to study the Innate Repair Activator ARA 290 in Diabetic Macular Edema
December 31, 2015 – Araim Pharmaceuticals announces a strategic partnership with Vault Bioventures to support development and commercialization of ARA 290 as well as other peptides within a novel family
December 22, 2015Araim Pharmaceuticals’ ARA 290 significantly improves islet cell function following islet cell transplantation in a model of Type 1 diabetes
December 16, 2014Molecular Medicine Issues 20th Anniversary Edition: Journal Focuses on the legacy and impact of Anthony Cerami’s groundbreaking work on diabetes
December 15, 2014New Study Published in Molecular Medicine Reports That Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
October 28, 2014 Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy
October 10, 2013Araim Pharmaceuticals’ ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission